GILD
Gilead Sciences, Inc.NASDAQHealthcare$139.71-0.42%OpenMarket Cap: $173.44B
As of 2026-04-06
Valuation
P/E (TTM)
20.38
PEG
0.01
P/B
7.67
P/S
5.89
EV/EBITDA
14.77
DCF Value
$165.27
FCF Yield
5.5%
Div Yield
2.3%
Margins & Returns
Gross Margin
80.8%
Operating Margin
37.4%
Net Margin
28.9%
ROE
41.0%
ROA
25.2%
ROIC
20.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $7.92B | 86.8% | $2.96B | $2.18B | $1.74 | $0.79 |
| FY 2025 | $29.44B | 86.7% | $11.82B | $8.51B | $6.78 | $3.16 |
| Q3 2025 | $7.77B | 79.8% | $3.33B | $3.05B | $2.43 | $0.79 |
| Q2 2025 | $7.08B | 78.8% | $2.47B | $1.96B | $1.56 | $0.79 |
| Q1 2025 | $6.67B | 76.9% | $2.24B | $1.31B | $1.04 | $0.79 |
| Q4 2024 | $7.57B | 79.1% | $2.45B | $1.78B | $1.42 | $0.77 |
| FY 2024 | $28.75B | 78.3% | $1.66B | $480.0M | $0.38 | $3.08 |
| Q3 2024 | $7.54B | 79.1% | $888.0M | $1.25B | $1.00 | $0.77 |
| Q2 2024 | $6.95B | 77.8% | $2.64B | $1.61B | $1.29 | $0.77 |
| Q1 2024 | $6.69B | 76.8% | $-4.32B | $-4.17B | $-3.34 | $0.77 |
| Q4 2023 | $7.11B | 70.6% | $1.61B | $1.43B | $1.14 | $0.75 |
| FY 2023 | $27.12B | 76.0% | $7.61B | $5.67B | $4.50 | $3.00 |